TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03612505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother groups using principles of UNICEF/World Health Organization's Care for Child Development
Description: The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future
Study: NCT02713347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT Intervention
Description: The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone.
Study: NCT02170597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS HPMC capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS HPMC capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS gelatine capsule
Study: NCT03392701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS infusion
Description: infusion of LPS 2 ng/kg over 5 minutes

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LPS infusion
Description: infusion of LPS 2 ng/kg over 5 minutes
Study: NCT04004715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid Enriched Whey Protein
Description: protein powder formulation that includes whey and free-form essential amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: commercially available whey protein isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Military Ration Entree
Description: chili and beans entree; current meal component of the meals ready to eat rations
Study: NCT00965042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
Study: NCT01819194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Study: NCT01782885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of PRP
Description: Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
Study: NCT03447067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided surgical
Description: has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
Study: NCT02765295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)
Description: The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Medical molecular mesh oxygen generator
Description: medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation.
Study: NCT03753529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep friction massage
Description: Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release
Description: First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: Stretching and transcutaneous electrical nerve stimulation
Study: NCT01352858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TolDC
Description: Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopy & saline irrigation alone
Study: NCT02340975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 + tremelimumab
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 + tremelimumab
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736+tremelimumab
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 + tremelimumab
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.
Study: NCT02321800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: 1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Study: NCT03012165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Drops (0.5%)
Description: ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Drops (0.1%)
Description: ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of ADX-102 Ophthalmic Drops
Description: Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
Study: NCT00720538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study: NCT00064116

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Rituximab 375 mg/m² i.v. day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Description: Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Description: Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
Study: NCT01746745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2940680
Description: Administered as solution by mouth
Study: NCT03535610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Embolization
Description: Uterine Embolization with PVA Microspheres
Study: NCT03987217

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Given orally

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete POWER resistance training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete POWER resistance training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01103648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Tablets of simvastatin 20 mg administered once a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablets of ezetimibe 10 mg administered once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Simvastatin plus Ezetimibe
Description: Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study.
Study: NCT04089384

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy Group
Description: Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
Study: NCT00911053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Sleep Schedule
Description: Subjects will maintain a regular sleep schedule of their choosing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light
Description: Subjects will be exposed to light.
Study: NCT01028144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Program
Description: A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
Study: NCT00696722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo + atazanavir
Description: Placebo treatment first, atazanavir treatment second~4 day treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir + placebo
Description: Atazanavir treatment first, placebo treatment second~4 day treatment
Study: NCT02723214

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain biopsy
Description: Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain biopsy
Description: Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
Study: NCT00704574

Intervention type: DRUG
Intervention: insulin detemir
Description: No extra intervention, only normal clinical practise for treatment of type 1 diabetes
Study: NCT00478426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT03447067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT
Description: For measuring the bone removeal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT
Description: for identifed the nerve
Study: NCT01229410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg Brimonidine Tartrate Implant
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg Brimonidine Tartrate Implant
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Study: NCT02929381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)
Description: NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
Study: NCT00390559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal system
Description: 21 mg nicotine transdermal system
Study: NCT02929381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy (Olympus CF-H180DL)
Description: Conventional colonoscopy performed without innovative techniques used in experimental arm.
Study: NCT04432376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: miconazole 2% oil
Description: Drug treatment of otomycosis for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: miconazole 2% oil
Description: Drug treatment of otomycosis for 14 days
Study: NCT04255108

Intervention type: DEVICE
Intervention: Cova Patch
Description: CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
Study: NCT03362008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zeropix
Description: administration of Zeropix
Study: NCT04432376

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle oil
Description: Placebo treatment of otomycosis for 14 days
Study: NCT03336476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Description: Patients will be intubated with the video laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Patients will be intubated with the direct laryngoscope
Study: NCT00726492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous short wave diathermy (CSWD)
Description: CSWD applied twice a week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous short wave diathermy (CSWD)
Description: CSWD applied twice a week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Hydrotherapy (exercise in water) attended twice a week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Hydrotherapy (exercise in water) attended twice a week for 4 weeks
Study: NCT01921699

Intervention type: PROCEDURE
Group type: OTHER
Intervention: taking blood samples from healthy people
Study: NCT03552900

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7cups Mobile App
Description: Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bliss
Description: Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
Study: NCT00470977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab injection (0.5 mg)
Description: ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
Study: NCT00390559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal system
Description: 21 mg nicotine transdermal system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal system
Description: Placebo nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal system
Description: Placebo nicotine patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine containing cigarette
Description: Nicotine containing cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine containing cigarette
Description: Nicotine containing cigarette
Study: NCT02233491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active lifestyle intervention
Description: Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No additional support other than lifestyle advice by clinician
Study: NCT02050828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Study: NCT03362008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zeropix
Description: administration of Zeropix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix®
Description: administration of Champix®
Study: NCT02050828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03362008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix®
Description: administration of Champix®
Study: NCT00582166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin) + Rituximab
Description: Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
Study: NCT03849196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-Asc
Description: PEG-Asc powder
Study: NCT02050828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham
Study: NCT04600453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.